Zacks: Brokers Anticipate Diplomat Pharmacy Inc. (DPLO) to book $ 0.23 per share

Equities analysts expect Diplomat Pharmacy Inc. (NYSE: DPLO) to report earnings per share (EPS) of $ 0.23 for the current quarter, according to Zacks. Seven analysts have provided estimates for Diplomat Pharmacy's earnings, with estimates ranging from $ 0.18 to $ 0.27. Diplomat Pharmacy recorded a profit of $ 0.25 per share during the same quarter of last year, which would indicate a negative annual growth of 8%. The company is expected to report its next revenue report on Monday, November 5.

According to Zacks analysts expect that Diplomat Pharmacy will report a profit per year of $ 0.87 per share for the current financial year, with EPS estimates of $ 0.79 to $ 0.92. For the next fiscal year, analysts expect the company to report a profit of $ 1.08 per share, with EPS estimates of $ 1.03 to $ 1.13. Zacks EPS calculations are an average based on a survey of research firms following Diplomat Pharmacy.

Diplomat Pharmacy (NYSE: DPLO) posted its results for the last time on Monday 6 August. The company reported $ 0.17 per share (EPS) for the quarter, with Thomson Reuters's consensus estimate of $ 0.23 with ($ 0.06) missing. The company had sales of $ 1.42 billion for the quarter compared with analyst estimates of $ 1.42 billion. Diplomat Pharmacy had a return on equity of 7.86% and a net margin of 0.06%. The quarterly turnover of Diplomat Pharmacy increased by 25.8% compared to the same quarter last year. During the same quarter of the previous year, the company posted $ 0.25 earnings per share.

DPLO has been the subject of several analyst reports. Zacks Investment Research lowered Diplomat Pharmacy from a & # 39; hold & # 39; credit to a & # 39; sell & # 39; rating in a research report on Tuesday 1 May. ValuEngine reduced Diplomat Pharmacy from a "buy" classification to a "hold" rating in a research report on Monday, July 2. Morgan Stanley raised their target price at Diplomat Pharmacy from $ 16.00 to $ 21.00 and gave the share an "equal weight" rating in a research report on Tuesday, July 3. Leerink Swann reformulated an outperform rating and set a target price of $ 33.00 on Diplomat Pharmacy shares in a research report on Friday, June 22nd. Finally, JPMorgan Chase & Co. Diplomat Pharmacy upgraded from a "neutral" rating to an "overweight" rating in a research report on Thursday, May 10. Eight analysts have rated the shares with a hold rating and six have assigned a buy-rating to the company. The stock currently has a consensus rating of "Hold" and a consensus price goal of $ 26.64.

In other news about Diplomat Pharmacy, director Shawn Tomasello sold 1,680 shares of the company's shares in a transaction that took place on Tuesday, June 5. The stock was sold at an average price of $ 24.27, for a total value of $ 40,773.60. After the sale, the director now holds 12,816 shares in the company, valued at approximately $ 311,044.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Director Jeffrey G. Park also sold 1,695 shares of the company stock in a transaction that took place on Monday 11 June. The shares were sold at an average price of $ 25.26 for a total value of $ 42,815.70. The information for this sale can be found here. Insiders have sold a total of 17,250 shares of company shares in the last 90 days, valued at $ 419,364. Business mixers own 24.70% of the company's shares.

A number of hedge funds and other institutional investors have recently added or reduced their stake in the business. Legal & General Group Plc increased its interest in Diplomat Pharmacy by 2.3% in the 1st quarter. Legal & General Group Plc now owns 100,097 shares of the company's shares with a value of $ 2,031,000 after the acquisition of 2,264 shares in the last quarter. Thrivent Financial for Lutherans increased the share in Diplomat Pharmacy in the first quarter by 8.7%. Thrivent Financial for Lutherans now owns 32,427 shares of the company worth $ 653,000 after the purchase of 2,589 additional shares in the last quarter. Rhumbline Advisers increased its stake in Diplomat Pharmacy by 2.5% in the first quarter. Rhumbline Advisors now holds 116,129 shares of the company's shares worth $ 2,340,000 after purchasing another 2,803 shares in the last quarter. OUDE Nationale Bancorp IN increased its interest in Diplomat Pharmacy by 24.9% during the second quarter. OUDE Nationale Bancorp IN now holds 15,891 shares of the company's shares worth $ 404,000 after the purchase of 3,148 additional shares in the last quarter. Finally, Envestnet Asset Management Inc. increased in the 4th quarter his interest in Diplomat Pharmacy with 27.1%. Envestnet Asset Management Inc. now owns 16,655 shares of the company's shares worth $ 334,000 after the purchase of 3,550 additional shares in the last quarter. Hedge funds and other institutional investors hold 73.88% of the company's shares.

Shares of the Diplomat Pharmacy stock fell by $ 0.19 during trading on Friday and had a price of $ 18.95. 14,480 shares of the company were exchanged, compared with the average volume of 1,422,281. The company has a market capitalization of $ 1.44 billion, a P / E ratio of 22.46 and a beta of 1.14. Diplomat Pharmacy has a 1-year low of $ 14.50 and a 1-year high of $ 28.74. The company has a current ratio of 0.91, a quick ratio of 0.57 and a debt-to-equity ratio of 0.58.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc. operates as an independent specialist pharmacy in the United States. The company is engaged in the storage, distribution and distribution of recipes for various producers of biotechnology and specialty pharmaceuticals. It also offers specialized infusion pharmacy, patient care coordination, clinical, compliance and continuation program, financial assistance for patients, training / consulting of specialized pharmacies, research on benefits, prior authorization, risk assessment and medication strategy, retail specialty and hub services, as well as clinical and administrative support services for hospitals and healthcare systems.

Read more: how to keep your portfolio in Google Finance

Receive a free copy of the Zacks research report on Diplomat Pharmacy (DPLO)

Visit for more information about research offers from Zacks Investment Research

Income History and Estimates for Diplomat Pharmacy (NYSE: DPLO)

Get news and ratings for Diplomat Pharmacy Daily – Enter your e-mail address below to receive a concise, daily summary of the latest news and ratings from analysts for Diplomat Pharmacy and related companies with the FREE daily email newsletter from

Source link

Leave a Reply